Weekly reads: court case, cancer stem cells, skin, pluripotency, & more

This was a busy week for me working on a grant due Friday and a bunch of other stuff including happily analyzing a bunch of data, but there were tons of interesting papers recently including on pluripotency.

chen et al fig 1e nat comm 2021 phc1
PHC1 as a pluripotency factor. “Co-immunostaining of Phc1 with Nanog and Sox2, or Gata6 and Sox2 in mouse E4.5 embryos. Scale bars, 31 μm.” The co-localization is striking. Chen et al ., Fig 1e Nat Comm 2021. 

California stem cell clinic court case on in the background

Along the way this week I was occasionally trying to listen in on the federal district court trial here in California. It is US vs. California Stem Cell Treatment Center, Cell Surgical Network, et al. I myself briefly testified in this trial last week.

I’m hoping to write up the experience of testifying and watching the trial in the next week or so if I have time.

This is a crucial case.

It in part tests the FDA’s authority to regulate stem cells as drugs, mainly related to their use by stem cell clinics. A Florida stem cell clinic case that in my view shares some similarities with the California one (e.g. with ‘fat stem cell’-related products at the heart of it) was decided in 2019 in the FDA’s favor. It is pending appeal.

On to the recommended stem cell paper reading.

Skin stem cells

Subscribe to Our Newsletter

Subscribe to Our Newsletter

Be the first to know about the latest developments in stem cell and regenerative medicine research.

Leave a Reply